First AD

Second AD

Misdiagnosis and Barriers to Early Detection of IgAN

Please discuss misdiagnosis and delayed diagnosis as it relates to IgAN? IgA nephropathy.

What are some of the primary barriers to timely detection of the disease, and how can these be addressed?

Videos

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Advancing IgAN Care: Exploring the Next Wave of Treatments

IgA nephropathy (IgAN) often faces challenges in timely diagnosis due to its nonspecific symptoms and the need for a kidney biopsy for definitive diagnosis. Misdiagnosis or delayed diagnosis can occur as symptoms like hematuria and proteinuria are common in other renal conditions. Barriers include limited awareness among healthcare providers, variability in disease presentation, and lack of specific biomarkers. Addressing these issues involves increasing awareness, improving access to diagnostic tools, and developing non-invasive biomarkers to facilitate earlier detection and intervention, ultimately improving patient outcomes.

Panelists discuss how misdiagnosis and delayed diagnosis of IgA nephropathy occur, highlighting the primary barriers to timely detection and strategies to overcome these challenges.